keyword
https://read.qxmd.com/read/38604215/endocrine-health-in-survivors-of-adult-onset-cancer
#1
REVIEW
Cornelia S Link-Rachner, Andy Göbel, Nikolai P Jaschke, Tilman D Rachner
Long-term survivors of cancer (ie, the patient who is considered cured or for whom the disease is under long-term control and unlikely to recur) are at an increased risk of developing endocrine complications such as hypothalamic-pituitary dysfunctions, hypogonadisms, osteoporosis, or metabolic disorders, particularly when intensive tumour-directed therapies are applied. Symptom severity associated with these conditions ranges from mild and subclinical to highly detrimental, affecting individual health and quality of life...
April 8, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38588685/glycaemic-index-as-part-of-the-diabetes-prevention-strategy
#2
JOURNAL ARTICLE
Gary Frost
No abstract text is available yet for this article.
April 5, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38588684/associations-of-the-glycaemic-index-and-the-glycaemic-load-with-risk-of-type-2-diabetes-in-127%C3%A2-594-people-from-20-countries-pure-a-prospective-cohort-study
#3
JOURNAL ARTICLE
Victoria Miller, David A Jenkins, Mahshid Dehghan, Kristie Srichaikul, Sumathy Rangarajan, Andrew Mente, Viswanathan Mohan, Sumathi Swaminathan, Rosnah Ismail, Maria Luz Diaz, Rekha M Ravindran, Katarzyna Zatonska, Ahmad Bahonar, Yuksel Altuntas, Rasha Khatib, Patricio Lopez-Jaramillo, Afzalhussein Yusufali, Karen Yeates, Jephat Chifamba, Romaina Iqbal, Rita Yusuf, Elizabeth Catherina Swart, Hu Bo, Guoliang Han, Xiaocong Li, Khalid F Alhabib, Annika Rosengren, Alvaro Avezum, Fernando Lanas, Salim Yusuf
BACKGROUND: The association between the glycaemic index and the glycaemic load with type 2 diabetes incidence is controversial. We aimed to evaluate this association in an international cohort with diverse glycaemic index and glycaemic load diets. METHODS: The PURE study is a prospective cohort study of 127 594 adults aged 35-70 years from 20 high-income, middle-income, and low-income countries. Diet was assessed at baseline using country-specific validated food frequency questionnaires...
April 5, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38588683/direct-to-consumer-services-improving-access-to-care-for-people-with-diabetes-and-obesity
#4
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
April 5, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38561012/type-1-diabetes-heterogeneity-in-heritability
#5
JOURNAL ARTICLE
Richard David Leslie
No abstract text is available yet for this article.
March 28, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38561011/familial-aggregation-and-heritability-of-childhood-onset-and-adult-onset-type-1-diabetes-a-swedish-register-based-cohort-study
#6
JOURNAL ARTICLE
Yuxia Wei, Shengxin Liu, Tomas Andersson, Maria Feychting, Ralf Kuja-Halkola, Sofia Carlsson
BACKGROUND: Type 1 diabetes in children is known to be highly heritable, but much less is known about the heritability of adult-onset type 1 diabetes. Thus, our objective was to compare the familial aggregation and heritability of type 1 diabetes in adults and children. METHODS: This Swedish nationwide register-based cohort study included individuals born from Jan 1, 1982, to Dec 31, 2010, identified through the Medical Birth Register who were linked to their parents, full siblings, half siblings, and cousins through the Multi-Generation Register (MGR)...
March 28, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38554714/how-clinically-relevant-is-statin-induced-diabetes
#7
JOURNAL ARTICLE
Hertzel C Gerstein, Marie Pigeyre
No abstract text is available yet for this article.
March 26, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38554713/effects-of-statin-therapy-on-diagnoses-of-new-onset-diabetes-and-worsening-glycaemia-in-large-scale-randomised-blinded-statin-trials-an-individual-participant-data-meta-analysis
#8
JOURNAL ARTICLE
(no author information available yet)
BACKGROUND: Previous meta-analyses of summary data from randomised controlled trials have shown that statin therapy increases the risk of diabetes, but less is known about the size or timing of this effect, or who is at greatest risk. We aimed to address these gaps in knowledge through analysis of individual participant data from large, long-term, randomised, double-blind trials of statin therapy. METHODS: We conducted a meta-analysis of individual participant data from randomised controlled trials of statin therapy that participated in the CTT Collaboration...
March 26, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38527466/disparities-in-fragility-fracture-and-osteoporosis-care-in-africa
#9
JOURNAL ARTICLE
Kate A Ward, Tafadzwa Madanhire, Kebba Marenah, Lisa K Micklesfield, Celia L Gregson
No abstract text is available yet for this article.
March 22, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38514241/tight-versus-liberal-blood-glucose-control-in-the-intensive-care-unit-special-considerations-for-patients-with-diabetes
#10
REVIEW
Christian von Loeffelholz, Andreas L Birkenfeld
Stress hyperglycaemia, hypoglycaemia, and diabetes are common in critically ill patients and related to clinical endpoints. To avoid complications related to hypoglycaemia and hyperglycaemia, it is recommended to start insulin therapy for the majority of critically ill patients with persistent blood glucose concentrations higher than 10·0 mmol/L (>180 mg/dL), targeting a range of 7·8-10·0 mmol/L (140-180 mg/dL). However, management and evidence-based targets for blood glucose control are under debate, particularly for patients with diabetes...
April 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38460527/undiagnosed-type-2-diabetes-an-invisible-risk-factor
#11
EDITORIAL
The Lancet Diabetes Endocrinology
No abstract text is available yet for this article.
March 6, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38452785/optimising-zoledronate-treatment-holiday-duration-without-loss-of-fracture-prevention
#12
JOURNAL ARTICLE
Matthew T Drake
No abstract text is available yet for this article.
April 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38452784/efficacy-and-safety-of-one-anastomosis-gastric-bypass-versus-roux-en-y-gastric-bypass-at-5-years-yomega-a-prospective-open-label-non-inferiority-randomised-extension-study
#13
RANDOMIZED CONTROLLED TRIAL
Maud Robert, Tigran Poghosyan, Delphine Maucort-Boulch, Alexandre Filippello, Robert Caiazzo, Adrien Sterkers, Lita Khamphommala, Fabian Reche, Vincent Malherbe, Adriana Torcivia, Toufic Saber, Dominique Delaunay, Carole Langlois-Jacques, Augustin Suffisseau, Sylvie Bin, Emmanuel Disse, François Pattou
BACKGROUND: The multicentre randomised trial YOMEGA (NCT02139813) comparing the one anastomosis gastric bypass (OAGB) with the Roux-en-Y gastric bypass (RYGB) confirmed the non-inferiority of OAGB on weight loss outcomes at 24 months. We aimed to report weight loss, metabolic, and safety outcomes at 5 years. METHODS: YOMEGA is a prospective, open-label, non-inferiority, randomised trial conducted at nine centres in France. Inclusion criteria were BMI of 40 kg/m2 or more, or 35 kg/m2 or more with comorbidities...
April 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38452783/duration-of-fracture-prevention-after-zoledronate-treatment-in-women-with-osteopenia-observational-follow-up-of-a-6-year-randomised-controlled-trial-to-10-years
#14
RANDOMIZED CONTROLLED TRIAL
Ian R Reid, Anne M Horne, Borislav Mihov, Usha Bava, Angela Stewart, Gregory D Gamble
BACKGROUND: We previously identified that zoledronate administered at 18-month intervals reduced fragility fractures by a third in a 6-year trial of women older than 65 years with osteopenia. This extension aims to identify the persistence of these effects. METHODS: Of the 2000 ambulant, community dwelling, postmenopausal women older than 65 years recruited in Auckland, New Zealand, with T-scores at the total hip or femoral neck in the range -1·0 to -2·5, we invited participants who received four doses of intravenous zoledronate, completed follow-up to year 6 of the core trial, did not have metabolic bone disease (other than osteoporosis), and were not using bone-active drugs into this 4-year observational study extension, during which further treatment was at the discretion of their own doctors...
April 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38452782/bariatric-tourism
#15
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
April 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38452781/long-term-trial-outcomes-of-roux-en-y-gastric-bypass-and-one-anastomosis-gastric-bypass-tipping-the-scale
#16
JOURNAL ARTICLE
Paulina Salminen
No abstract text is available yet for this article.
March 4, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38437851/reversibility-of-congenital-hypogonadotropic-hypogonadism-lessons-from-a-rare-disease
#17
JOURNAL ARTICLE
Bradley D Anawalt
No abstract text is available yet for this article.
March 1, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38437850/classes-and-predictors-of-reversal-in-male-patients-with-congenital-hypogonadotropic-hypogonadism-a-cross-sectional-study-of-six-international-referral-centres
#18
JOURNAL ARTICLE
Andrew A Dwyer, Isabella R McDonald, Biagio Cangiano, Luca Giovanelli, Luigi Maione, Leticia F G Silveira, Taneli Raivio, Ana Claudia Latronico, Jacques Young, Richard Quinton, Marco Bonomi, Luca Persani, Stephanie B Seminara, Christopher S Lee
BACKGROUND: Although some male patients with congenital hypogonadotropic hypogonadism (CHH) undergo spontaneous reversal following treatment, predictors of reversal remain elusive. We aimed to assemble the largest cohort of male patients with CHH reversal to date and identify distinct classes of reversal. METHODS: This multicentre cross-sectional study was conducted in six international CHH referral centres in Brazil, Finland, France, Italy, the UK, and the USA...
March 1, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38430914/type-2-diabetes-remission-weight-maintenance-in-the-spotlight
#19
JOURNAL ARTICLE
Shahrad Taheri
No abstract text is available yet for this article.
February 28, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38423026/5-year-follow-up-of-the-randomised-diabetes-remission-clinical-trial-direct-of-continued-support-for-weight-loss-maintenance-in-the-uk-an-extension-study
#20
JOURNAL ARTICLE
Michael Ej Lean, Wilma S Leslie, Alison C Barnes, Naomi Brosnahan, George Thom, Louise McCombie, Tara Kelly, Keaton Irvine, Carl Peters, Sviatlana Zhyzhneuskaya, Kieren G Hollingsworth, Ashley J Adamson, Falko F Sniehotta, John C Mathers, Yvonne McIlvenna, Paul Welsh, Alex McConnachie, Alasdair McIntosh, Naveed Sattar, Roy Taylor
BACKGROUND: In DiRECT, a randomised controlled effectiveness trial, weight management intervention after 2 years resulted in mean weight loss of 7·6 kg, with 36% of participants in remission of type 2 diabetes. Of 36 in the intervention group who maintained over 10 kg weight loss at 2 years, 29 (81%) were in remission. Continued low-intensity dietary support was then offered up to 5 years from baseline to intervention participants, aiming to maintain weight loss and gain clinical benefits...
February 26, 2024: Lancet Diabetes & Endocrinology
keyword
keyword
100954
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.